pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·1h ago·1 min read
save

FDA again turns back Capricor Duchenne cell therapy

Nov 21, 2026·read at BioPharma Dive ↗

In an unusual statement, the FDA accused Capricor of “serious data integrity violations” that compromised its study findings and led to deramiocel’s second rejection since 2025.

source

Reporting by BioPharma Dive.

read at BioPharma Dive ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoWill the first approved psychedelic become a blockbuster?BioPharma Dive
  • 1d agoErasca data add to pressure facing Revolution’s breakthrough cancer drugBioPharma Dive
  • 1d agoCelldex drug stumbles in eczema; Epigenetic editing startup cuts staffBioPharma Dive
  • 1d agoThis week in charts: Biotech investors’ China bets are already paying offBioPharma Dive
  • 2d agoSanofi gains FDA clearance for Gaucher disease pillBioPharma Dive